Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

The anti-cancer drugs curaxins target spatial genome organization.

Kantidze OL, Luzhin AV, Nizovtseva EV, Safina A, Valieva ME, Golov AK, Velichko AK, Lyubitelev AV, Feofanov AV, Gurova KV, Studitsky VM, Razin SV.

Nat Commun. 2019 Mar 29;10(1):1441. doi: 10.1038/s41467-019-09500-7.

2.

Chromatin Stability as a Target for Cancer Treatment.

Gurova KV.

Bioessays. 2019 Jan;41(1):e1800141. doi: 10.1002/bies.201800141. Review.

PMID:
30566250
3.

Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins.

Chang HW, Valieva ME, Safina A, Chereji RV, Wang J, Kulaeva OI, Morozov AV, Kirpichnikov MP, Feofanov AV, Gurova KV, Studitsky VM.

Sci Adv. 2018 Nov 7;4(11):eaav2131. doi: 10.1126/sciadv.aav2131. eCollection 2018 Nov.

4.

Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene.

Sandlesh P, Juang T, Safina A, Higgins MJ, Gurova KV.

PLoS One. 2018 Jun 28;13(6):e0199785. doi: 10.1371/journal.pone.0199785. eCollection 2018.

5.

Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs.

Nesher E, Safina A, Aljahdali I, Portwood S, Wang ES, Koman I, Wang J, Gurova KV.

Cancer Res. 2018 Mar 15;78(6):1431-1443. doi: 10.1158/0008-5472.CAN-17-2690. Epub 2018 Jan 16.

6.

Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas.

Kim M, Neznanov N, Wilfong CD, Fleyshman DI, Purmal AA, Haderski G, Stanhope-Baker P, Burkhart CA, Gurova KV, Gudkov AV, Skitzki JJ.

Cancer Res. 2016 Nov 15;76(22):6620-6630. doi: 10.1158/0008-5472.CAN-15-2764. Epub 2016 Sep 28.

7.

Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.

Barone TA, Burkhart CA, Safina A, Haderski G, Gurova KV, Purmal AA, Gudkov AV, Plunkett RJ.

Neuro Oncol. 2017 Feb 1;19(2):186-196. doi: 10.1093/neuonc/now141.

8.

Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.

Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, Stark GR, Venere M.

Cancer Res. 2016 Apr 15;76(8):2432-42. doi: 10.1158/0008-5472.CAN-15-2162. Epub 2016 Feb 26.

9.

Inhibition of the FACT Complex Reduces Transcription from the Human Cytomegalovirus Major Immediate Early Promoter in Models of Lytic and Latent Replication.

O'Connor CM, Nukui M, Gurova KV, Murphy EA.

J Virol. 2016 Mar 28;90(8):4249-4253. doi: 10.1128/JVI.02501-15. Print 2016 Apr.

10.

Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.

Carter DR, Murray J, Cheung BB, Gamble L, Koach J, Tsang J, Sutton S, Kalla H, Syed S, Gifford AJ, Issaeva N, Biktasova A, Atmadibrata B, Sun Y, Sokolowski N, Ling D, Kim PY, Webber H, Clark A, Ruhle M, Liu B, Oberthuer A, Fischer M, Byrne J, Saletta F, Thwe le M, Purmal A, Haderski G, Burkhart C, Speleman F, De Preter K, Beckers A, Ziegler DS, Liu T, Gurova KV, Gudkov AV, Norris MD, Haber M, Marshall GM.

Sci Transl Med. 2015 Nov 4;7(312):312ra176. doi: 10.1126/scitranslmed.aab1803.

11.

Small-molecule xenomycins inhibit all stages of the Plasmodium life cycle.

Erath J, Gallego-Delgado J, Xu W, Andriani G, Tanghe S, Gurova KV, Gudkov A, Purmal A, Rydkina E, Rodriguez A.

Antimicrob Agents Chemother. 2015 Mar;59(3):1427-34. doi: 10.1128/AAC.04704-14. Epub 2014 Dec 15.

12.

Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.

Burkhart C, Fleyshman D, Kohrn R, Commane M, Garrigan J, Kurbatov V, Toshkov I, Ramachandran R, Martello L, Gurova KV.

Oncotarget. 2014 Nov 30;5(22):11038-53.

13.

Complex mutual regulation of facilitates chromatin transcription (FACT) subunits on both mRNA and protein levels in human cells.

Safina A, Garcia H, Commane M, Guryanova O, Degan S, Kolesnikova K, Gurova KV.

Cell Cycle. 2013 Aug 1;12(15):2423-34. doi: 10.4161/cc.25452. Epub 2013 Jun 28.

14.

Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers.

Garcia H, Miecznikowski JC, Safina A, Commane M, Ruusulehto A, Kilpinen S, Leach RW, Attwood K, Li Y, Degan S, Omilian AR, Guryanova O, Papantonopoulou O, Wang J, Buck M, Liu S, Morrison C, Gurova KV.

Cell Rep. 2013 Jul 11;4(1):159-73. doi: 10.1016/j.celrep.2013.06.013. Epub 2013 Jul 3.

15.

Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.

Koman IE, Commane M, Paszkiewicz G, Hoonjan B, Pal S, Safina A, Toshkov I, Purmal AA, Wang D, Liu S, Morrison C, Gudkov AV, Gurova KV.

Cancer Prev Res (Phila). 2012 Aug;5(8):1025-35. doi: 10.1158/1940-6207.CAPR-11-0529. Epub 2012 Jun 11.

16.

Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.

Gasparian AV, Burkhart CA, Purmal AA, Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA, Pal S, Safina A, Sviridov S, Koman IE, Veith J, Komar AA, Gudkov AV, Gurova KV.

Sci Transl Med. 2011 Aug 10;3(95):95ra74. doi: 10.1126/scitranslmed.3002530.

17.

Inflammation and p53: A Tale of Two Stresses.

Gudkov AV, Gurova KV, Komarova EA.

Genes Cancer. 2011 Apr;2(4):503-16. doi: 10.1177/1947601911409747.

18.

Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugs.

Gasparian AV, Neznanov N, Jha S, Galkin O, Moran JJ, Gudkov AV, Gurova KV, Komar AA.

J Virol. 2010 Sep;84(18):9390-7. doi: 10.1128/JVI.02569-09. Epub 2010 Jul 14.

19.

Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer.

Narizhneva NV, Tararova ND, Ryabokon P, Shyshynova I, Prokvolit A, Komarov PG, Purmal AA, Gudkov AV, Gurova KV.

Cell Cycle. 2009 Dec 15;8(24):4155-67. Epub 2009 Dec 13.

20.

Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications.

Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, Gasparian AV, Banerjee AK, Almasan A, Fairchild RL, Gudkov AV.

Cell Cycle. 2009 Dec;8(23):3960-70. Epub 2009 Dec 25.

21.

Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.

Burkhart CA, Watt F, Murray J, Pajic M, Prokvolit A, Xue C, Flemming C, Smith J, Purmal A, Isachenko N, Komarov PG, Gurova KV, Sartorelli AC, Marshall GM, Norris MD, Gudkov AV, Haber M.

Cancer Res. 2009 Aug 15;69(16):6573-80. doi: 10.1158/0008-5472.CAN-09-1075. Epub 2009 Aug 4.

22.

9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.

Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV.

Oncogene. 2009 Feb 26;28(8):1151-61. doi: 10.1038/onc.2008.460. Epub 2009 Jan 12.

PMID:
19137016
23.

Small-molecule inhibitor which reactivates p53 in human T-cell leukemia virus type 1-transformed cells.

Jung KJ, Dasgupta A, Huang K, Jeong SJ, Pise-Masison C, Gurova KV, Brady JN.

J Virol. 2008 Sep;82(17):8537-47. doi: 10.1128/JVI.00690-08. Epub 2008 Jun 11.

24.

Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation.

Logunov DY, Scheblyakov DV, Zubkova OV, Shmarov MM, Rakovskaya IV, Gurova KV, Tararova ND, Burdelya LG, Naroditsky BS, Ginzburg AL, Gudkov AV.

Oncogene. 2008 Jul 31;27(33):4521-31. doi: 10.1038/onc.2008.103. Epub 2008 Apr 14.

25.

p53 determines multidrug sensitivity of childhood neuroblastoma.

Xue C, Haber M, Flemming C, Marshall GM, Lock RB, MacKenzie KL, Gurova KV, Norris MD, Gudkov AV.

Cancer Res. 2007 Nov 1;67(21):10351-60.

26.

Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity.

Tararova ND, Narizhneva N, Krivokrisenko V, Gudkov AV, Gurova KV.

Prostate. 2007 Dec 1;67(16):1801-15.

27.

Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation.

Gorbachev AV, Gasparian AV, Gurova KV, Gudkov AV, Fairchild RL.

Eur J Immunol. 2007 Aug;37(8):2257-67.

28.

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors.

Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, Gudkov AV.

Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17448-53. Epub 2005 Nov 15.

29.

Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas.

Kichina JV, Zeremski M, Aris L, Gurova KV, Walker E, Franks R, Nikitin AY, Kiyokawa H, Gudkov AV.

Oncogene. 2006 Feb 9;25(6):857-66.

PMID:
16170338
30.

p53 pathway in renal cell carcinoma is repressed by a dominant mechanism.

Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV.

Cancer Res. 2004 Mar 15;64(6):1951-8.

31.

Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.

Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, Gudkov AV.

Cancer Res. 2003 Jun 1;63(11):2905-12.

32.

Paradoxical role of apoptosis in tumor progression.

Gurova KV, Gudkov AV.

J Cell Biochem. 2003 Jan 1;88(1):128-37. Review.

PMID:
12461782
33.

Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor.

Gurova KV, Kwek SS, Koman IE, Komarov AP, Kandel E, Nikiforov MA, Gudkov AV.

Cancer Biol Ther. 2002 Jan-Feb;1(1):39-44.

PMID:
12170763
34.

Expression of prostate specific antigen (PSA) is negatively regulated by p53.

Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, Gudkov AV.

Oncogene. 2002 Jan 3;21(1):153-7.

35.

Structure and regulation of the mouse ing1 gene. Three alternative transcripts encode two phd finger proteins that have opposite effects on p53 function.

Zeremski M, Hill JE, Kwek SS, Grigorian IA, Gurova KV, Garkavtsev IV, Diatchenko L, Koonin EV, Gudkov AV.

J Biol Chem. 1999 Nov 5;274(45):32172-81.

36.

[Growth-regulating effect of normal Syrian hamster embryonal fibroblasts on cells transformed by various agents].

Gurova KV.

Dokl Akad Nauk. 1996 Jul;349(3):414-7. Russian. No abstract available.

PMID:
8963231

Supplemental Content

Loading ...
Support Center